Newsletter
June 1, 2012
- Kasznar Leonardos
Newsletter 2012.03 – The debate over ANVISA’s role in the examination of pharmaceutical patent applications continues
As you may be aware, due to article 229-C of the Brazilian IP Law, as amended by Law No. 10,196/01, whenever a patent application claims a pharmaceutical product or process, consent from the National Sanitary Surveillance Agency (ANVISA) is also required prior to granting the desired patent. This provision, however, has been the source of never-ending controversy and subject to growing attacks since it entered into effect in 2001.
The lack of statutory power of ANVISA to analyse patentability requirements of pharma applications was supported by the Attorney-General’s Office in legal opinions published in 2009 and 2011. Indeed, in their opinion, ANVISA should only make health-based assessments of applications sent for prior consent; prior consent should only be denied to applications in instances that granting the patents would pose health risks. How ANVISA would assess “health risks” on the basis of the information included in patent applications was left unanswered though.
Last related news
April 28, 2022
Have you heard about the Web 3.0?
Web 3.0 is the new global trend that will impact modern society and the way people relate to the internet. It refers … Have you heard about the Web 3.0?
March 28, 2022
Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
On March 17, 2022, the BPTO released the INPI/CPAPD technical note No. 01/2022, which provides guidance on the patentability of inventions involving … Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
February 11, 2022
Data Protection becomes a fundamental right in Brazil
Yesterday (Feb. 10, 2022), the Brazilian Senate approved the Constitutional Amendment no. 115/2022, originated in the Proposal for Constitutional Amendment no. 17/2019, … Data Protection becomes a fundamental right in Brazil